Dexpramipexole (dihydrochloride)

Dexpramipexole dihydrochloride ((R) -Pramipexole dihydrochloride) is a neuroprotective agent and weak non-ergoline dopamine agonist.

Product Specifications

CAS Number

[104632-27-1]

Product Name Alternative

(R) -Pramipexole (dihydrochloride) ; R- (+) -Pramipexole (dihydrochloride) ; KNS-760704 (dihydrochloride)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Dexpramipexole-dihydrochloride.html

Purity

99.94

Solubility

DMSO : ≥ 100 mg/mL|H2O : 100 mg/mL (ultrasonic)

Smiles

NC(S1)=NC2=C1C[C@H](NCCC)CC2.[H]Cl.[H]Cl

Molecular Formula

C10H19Cl2N3S

Molecular Weight

284.26

Precautions

H302, H315, H319, H335

References & Citations

[1]Rudnicki SA, Berry JD, Ingersoll E, et al. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Jan;14 (1) :44-51.|[2]Alavian KN, Dworetzky SI, Bonanni L, et al. Effects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. Brain Res. 2012 Mar 29;1446:1-11.|[3]Cudkowicz M, Bozik ME, Ingersoll EW, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011 Nov 20;17 (12) :1652-6.|[4]Bozik ME, Mather JL, Kramer WG, et al. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects. J Clin Pharmacol. 2011 Aug;51 (8) :1177-85.|[5]Cheah BC, Kiernan MC. Dexpramipexole, the R (+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010 Dec;13 (12) :911-20.